PART 1 (monotherapy and combo therapy with KQB198): Histologically confirmed diagnosis of a solid tumor malignancy with either a KRAS G12C or KRAS G12S mutation.
PART 1 (combo therapy with Cetuximab) \& PART 2: Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with either a KRAS G12C or KRAS G12S mutation.
Unresectable or metastatic disease
No available treatment with curative intent
Adequate organ function
Measurable disease per RECIST v1.1
You may not be if
Active primary central nervous system tumors
Cardiac abnormalities
Active interstitial lung disease
Unable to swallow or GI condition that prevents absorption for patients in KQB198 combination cohorts
Clareo Health | A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
